Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis.

Guedon AF, Cacoub P, Carrat F, Espitia O, Mirouse A, Ghrenassia E, Fain O, Mekinian A, Saadoun D

Open source

DOI
10.1161/circulationaha.126.080365
Published
2026 Aug 29
Container
Circulation
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1161/circulationaha.126.080365,
  title = {Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis.},
  author = {Guedon AF and Cacoub P and Carrat F and Espitia O and Mirouse A and Ghrenassia E and Fain O and Mekinian A and Saadoun D},
  year = {2026},
  journal = {Circulation},
  doi = {10.1161/circulationaha.126.080365},
  url = {https://doi.org/10.1161/circulationaha.126.080365}
}

RIS

TY  - JOUR
TI  - Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis.
AU  - Guedon AF
AU  - Cacoub P
AU  - Carrat F
AU  - Espitia O
AU  - Mirouse A
AU  - Ghrenassia E
AU  - Fain O
AU  - Mekinian A
AU  - Saadoun D
PY  - 2026
JO  - Circulation
DO  - 10.1161/circulationaha.126.080365
UR  - https://doi.org/10.1161/circulationaha.126.080365
ER  - 

APA

AF, G., P, C., F, C., O, E., A, M., E, G., O, F., A, M., & D, S. (2026). Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis.. Circulation. https://doi.org/10.1161/circulationaha.126.080365

Source records